A landmark oncology deal dominated the health and biotech space, with GSK's $10.6bn acquisition of Nuvalent setting the tone for a session that also brought Phase 1 trial readouts, a clinical access programme reactivation, and a surgical robotics milestone. Across the sector, the direction of travel was firmly towards late-stage pipeline reinforcement and next-generation clinical platforms.
Imaging Biometrics publishes gallium trial data and reopens access programme
Imaging Biometrics (AIM:IBAI) published results from its Phase 1 gallium-based imaging trial and announced the reactivation of an expanded access programme for up to 20 patients. The clinical update marks a meaningful step forward in the company's development pipeline, though the shares slipped 2.5% to 0.78p on the day.
Seaport Therapeutics advances GlyphAgo into Phase 2 on strong Phase 1 data
PureTech Health (NASDAQ:PRTC) subsidiary Seaport Therapeutics announced it will advance GlyphAgo into Phase 2 development after positive multiple-dose Phase 1 results. Co-Founder and Chief Executive Daphne Zohar said the data "substantially derisk our future clinical development approach" and strengthen GlyphAgo's differentiated profile. PureTech shares were quoted at 124.4p.
GSK acquires Nuvalent for $10.6bn to bolster lung-cancer pipeline
GSK (LSE:GSK) struck a deal to acquire Nuvalent for $10.6bn, adding two late-stage assets targeting distinct forms of non-small cell lung cancer. Chief Commercial Officer Luke Miels described the two lead products as "potential best-in-class assets" that could reach market this year pending FDA approval, offering significant new treatment options to patients. GSK shares fell 1.46% to 1885.0p on the news, a common market reaction to large-scale acquisition announcements as investors weigh the cost of the deal against its strategic rationale.
Smith+Nephew completes first CORI XT robotic cases in knee and shoulder
Smith+Nephew completed the inaugural clinical procedures using its next-generation CORI XT handheld robotics platform, spanning both knee and shoulder arthroplasty. The milestone includes what the company describes as the first robotic shoulder arthroplasty cases performed with the system, marking a significant expansion of the CORI XT's clinical footprint beyond its initial knee application.
